Corpus Intelligence IC Memo — UT SOUTHWESTERN UNIVERSITY HOSP 2026-04-26 09:55 UTC
IC Memo — UT SOUTHWESTERN UNIVERSITY HOSP
Investment Committee Memorandum | TX | 737 beds | Grade B | EBITDA uplift $167.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UT SOUTHWESTERN UNIVERSITY HOSP

CCN 450044 | DALLAS, TX | 737 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UT SOUTHWESTERN UNIVERSITY HOSP is a 737-bed large academic medical center in DALLAS, TX with $2.28B in net patient revenue and a -4.6% operating margin. The hospital serves a payer mix of 26.0% Medicare, 0.4% Medicaid, and 73.6% commercial.

Thesis: Undervalued. Our ML models identify $167.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -4.6% to 2.8% (+736bps).

Net Revenue HCRIS$2.28B
Current EBITDA COMPUTED$-104.8M
Operating Margin COMPUTED-4.6%
Occupancy HCRIS78.0%
Revenue / Bed COMPUTED$3.1M
Net-to-Gross HCRIS34.8%
Distress Probability ML40.6%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
41
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -4.6% places it below the state median. Among 41 size-comparable peers (368-1474 beds), the median margin is 2.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (368-1474), prioritizing same-state peers. 41 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UT SOUTHWESTERN UNIVERSITY HOS (Target)TX737$2.28B-4.6%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
MEMORIAL HERMANN TEXAS MEDICALTX1089$2.64B2.8%
THE METHODIST HOSPITALTX966$2.63B5.2%
TEXAS CHILDRENS HOSPITALTX863$2.50B-29.9%
MEMORIAL HERMANN HOSPITAL SYSTX1417$2.15B7.3%
SCOTT AND WHITE MEMORIAL HOSPITX616$1.85B-10.5%
CHILDRENS MEDICAL CENTER OF DATX377$1.56B10.3%
COOK CHILDRENS MEDICAL CENTERTX423$1.51B16.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $167.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$47.9M+210bp18mo
Cost to Collect4.5%2.5%$45.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$45.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$27.7M+122bp9mo
Clean Claim Rate88.0%96.0%$1.5M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$47.9M
Cost to Collect
$45.6M
Denial Rate Reduction
$45.2M
A/R Days Reduction
$27.7M
Clean Claim Rate
$1.5M
Total EBITDA Uplift$167.9M
Current EBITDA$-104.8M
+ RCM Uplift+$167.9M
Pro Forma EBITDA$63.0M
Current Margin-4.6%
Pro Forma Margin2.8%
WC Released (1x)$87.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-161.3M$987.1M0.00x-100.0%
Base (11x exit)10.0x11.0x$-161.3M$1.03B0.00x-100.0%
Bull Case9.0x11.0x$-145.2M$1.53B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-145.2M$1.63B0.00x-100.0%
Bear Case11.0x10.0x$-177.4M$200.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-177.4M$162.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 41 hospitals with 368-1474 beds
  • Same-state prioritization (n=42)
  • Comp margins: P25=-10.5% / P50=2.8% / P75=12.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.